Department of Pathology Hirosaki University School of Medicine, Hirosaki, Aomori, Japan.
J Surg Oncol. 2011 Jun 1;103(7):669-73. doi: 10.1002/jso.21880. Epub 2011 Feb 28.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most extremely aggressive cancers with a poor prognosis after curative resection. L1 cell adhesion molecule (L1CAM) is a 200-220 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily, which has been shown to affect the prognosis of several cancers. No clinicopathological significance of L1CAM expression has been examined at the invasive front of PDAC. In this study, we examined the relationship between L1CAM expression and clinicopathological features in PDAC by immunohistochemistry.
One hundred seven surgically resected specimens of PDAC were immunohistochemically examined using a monoclonal antibody against L1CAM.
Positive expression of L1CAM was found in 23 of 107 cases with PDAC. In most cases (21/23), L1CAM expression was localized at the invasive front of the tumor tissue. Positive expression of L1CAM was significantly correlated with the histological grade, lymph node involvement, and distant metastasis. In univariate analysis, a positive expression of L1CAM was associated with short overall survival (P = 0.0002), and this was significant in multivariate analysis (P = 0.009).
L1CAM could play an important role in the invasive process in vivo, and is thought to be a good indicator of prognosis in PDAC.
胰腺导管腺癌(PDAC)是预后最差的侵袭性极强的癌症之一,即使经过根治性切除后也是如此。L1 细胞黏附分子(L1CAM)是一种 200-220 kDa 的免疫球蛋白超家族的 I 型跨膜糖蛋白,已被证明会影响多种癌症的预后。目前尚未对 PDAC 侵袭前沿的 L1CAM 表达的临床病理意义进行研究。本研究通过免疫组织化学方法检测 L1CAM 在 PDAC 中的表达与临床病理特征之间的关系。
用针对 L1CAM 的单克隆抗体对 107 例手术切除的 PDAC 标本进行免疫组织化学检查。
在 107 例 PDAC 中,有 23 例发现 L1CAM 阳性表达。在大多数病例(21/23)中,L1CAM 表达定位于肿瘤组织的侵袭前沿。L1CAM 阳性表达与组织学分级、淋巴结受累和远处转移显著相关。单因素分析显示,L1CAM 阳性表达与总生存期较短显著相关(P=0.0002),且在多因素分析中也有统计学意义(P=0.009)。
L1CAM 可能在体内侵袭过程中发挥重要作用,被认为是 PDAC 预后的良好指标。